Evidence map›Paper›PMID 27625996›Full record

ArticleFrontiers in cellular and infection microbiology2016

From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization.

Daniel Tapia, Brittany N Ross, Anjana Kalita, Mridul Kalita, Christopher L Hatcher, Laura A Muruato, Alfredo G Torres

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Diversity ofMicroorganisms · 2023
    Review
  5. A new candidate epitope-based vaccine against PspA PhtD ofFrontiers in cellular and infection microbiology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel TapiaDepartment of Microbiology and Immunology, University of Texas Medical Branch Galveston, TX, USA.
Brittany N RossDepartment of Microbiology and Immunology, University of Texas Medical Branch Galveston, TX, USA.
Anjana KalitaDepartment of Microbiology and Immunology, University of Texas Medical Branch Galveston, TX, USA.
Mridul KalitaDepartment of Internal Medicine, University of Texas Medical Branch Galveston, TX, USA.
Christopher L HatcherDepartment of Microbiology and Immunology, University of Texas Medical Branch Galveston, TX, USA.
Laura A MuruatoDepartment of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA; Institute for Translational Sciences, University of Texas Medical BranchGalveston, TX, USA.
Alfredo G TorresDepartment of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA; Institute for Translational Sciences, University of Texas Medical BranchGalveston, TX, USA; Department of Pathology and Sealy Center for Vaccine Development University of Texas Medical BranchGalveston, TX, USA.

Funding

PREPing to a Biomedical PhDR25GM069285 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VARGAS, GRACIE · 2009 to 2016
$2.3M
NIGMS NIH HHS R25 GM069285
6 · The paper itself

Abstract

Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a leading cause of foodborne illnesses worldwide and is a common serotype linked to hemorrhagic colitis and an important cause of hemolytic uremic syndrome (HUS). Treatment of EHEC O157:H7 infections is complicated, as antibiotics can exacerbate Shiga toxin (Stx) production and lead to more severe symptoms including HUS. To date, no vaccines have been approved for human use, exposing a void in both treatment and prevention of EHEC O157:H7 infections. Previously, our lab has shown success in identifying novel vaccine candidates via bio- and immunoinformatics approaches, which are capable of reducing bacterial colonization in an in vivo model of intestinal colonization. In this study, we further characterized 17 of the identified vaccine candidates at the bioinformatics level and evaluated the protective capacity of the top three candidates when administered as DNA vaccines in our murine model of EHEC O157:H7 colonization. Based on further immunoinformatic predictions, these vaccine candidates were expected to induce neutralizing antibodies in a Th2-skewed immunological response. Immunization of BALB/c mice with two of these candidates resulted in reduced bacterial colonization following EHEC O157:H7 challenge. Additionally, immune sera was shown to prevent bacterial adhesion in vitro to Caco-2 cells. Together, this study provides further validation of our immunoinformatic analyses and identifies promising vaccine candidates against EHEC O157:H7.

Indexed as

AnimalsAntibodies, BacterialBacterial AdhesionCaco-2 CellsComputational BiologyEpitopesEscherichia coli InfectionsEscherichia coli O157Escherichia coli VaccinesHumansMice, Inbred BALB CVaccines, DNAAntibodies, BacterialEpitopesEscherichia coli VaccinesVaccines, DNAbioinformaticsEscherichia coli O157:H7immunoinformaticstype III secretion systemvaccine

Identifiers

PMID27625996
PMCPMC5003871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.